IVF News & Events

INVO Fertility announced the adoption of time-lapse incubation technology at its Wisconsin clinic. "This integration reflects INVO's commitment to providing high-quality, modern laboratory care and innovative patient solutions, and to investing in laboratory excellence and clinical quality across its growing network of clinics," the company said.

INVO Fertility announced that its Wisconsin Fertility Institute clinic has joined the Progyny network. Progyny provides fertility and family-building benefits to an estimated 7.2 million covered lives through over 600 employers and plan sponsors nationwide. WFI's participation in the Progyny network significantly expands the clinic's access to employer-sponsored patients and meaningfully increases its addressable market within Wisconsin and surrounding regions. Eligible patients now have in-network access to WFI's comprehensive suite of reproductive services, including diagnostic testing, in vitro fertilization, fertility preservation, and other advanced treatment options. Progyny's clinically integrated benefit design simplifies financial and administrative processes for patients, reducing barriers to care and supporting improved treatment utilization and outcomes. Progyny has become a major force in addressing the greatest patient challenges in the fertility industry-access and affordability.

INVO Fertility announced that it has successfully closed the previously announced acquisition of Family Beginnings, P.C., a fertility clinic serving patients across Indiana and the broader Midwest. The transaction was completed in accordance with the terms of the definitive purchase agreement first announced on December 17, 2025

INVO Fertility announced the final issuance of a U.S. patent covering a modified version of its proprietary INVOcell device. The patent became effective on February 10, 2026, providing intellectual property protection on the INVOcell device through 2040. "We are pleased to see our previously announced patent allowance conclude with this official issuance, which marks an important milestone for INVO Fertility as we continue to strengthen the intellectual property foundation around the INVOcell platform," said Steve Shum, CEO of INVO Fertility. "INVOcell provides an additional treatment method in the fertility market, enabling fertilization and early embryo development to occur within the patient's body rather than a traditional laboratory incubator. This expanded IP coverage supports our growth strategy and our mission to deliver high-quality fertility care through ongoing innovation."